Shares of ABIOMED, Inc. (NASDAQ:ABMD) have been given an average recommendation of “Buy” by the ten research firms that are covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $199.60.

Several equities research analysts have recently issued reports on the company. Jefferies Group raised their price target on ABIOMED to $250.00 and gave the company a “buy” rating in a research report on Friday. BidaskClub raised ABIOMED from a “hold” rating to a “buy” rating in a research report on Thursday. Piper Jaffray Companies reaffirmed a “buy” rating on shares of ABIOMED in a research report on Thursday, January 4th. Zacks Investment Research raised ABIOMED from a “hold” rating to a “buy” rating and set a $213.00 price target on the stock in a research report on Friday, December 29th. Finally, SunTrust Banks reaffirmed a “buy” rating and issued a $195.00 price target on shares of ABIOMED in a research report on Wednesday, November 1st.

In related news, Director Dorothy E. Puhy sold 6,364 shares of ABIOMED stock in a transaction dated Monday, October 30th. The stock was sold at an average price of $179.08, for a total transaction of $1,139,665.12. Following the sale, the director now directly owns 39,532 shares of the company’s stock, valued at $7,079,390.56. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, VP Michael G. Howley sold 10,000 shares of ABIOMED stock in a transaction dated Monday, October 30th. The stock was sold at an average price of $178.64, for a total value of $1,786,400.00. Following the sale, the vice president now directly owns 56,757 shares in the company, valued at $10,139,070.48. The disclosure for this sale can be found here. Company insiders own 7.00% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in ABMD. Koch Industries Inc. grew its position in ABIOMED by 40,431.3% during the second quarter. Koch Industries Inc. now owns 799,277 shares of the medical equipment provider’s stock worth $794,000 after buying an additional 797,305 shares in the last quarter. Janus Henderson Group PLC grew its position in ABIOMED by 102.0% during the third quarter. Janus Henderson Group PLC now owns 1,076,829 shares of the medical equipment provider’s stock worth $181,553,000 after buying an additional 543,793 shares in the last quarter. Wells Fargo & Company MN grew its position in ABIOMED by 2,219.4% during the third quarter. Wells Fargo & Company MN now owns 364,427 shares of the medical equipment provider’s stock worth $61,443,000 after buying an additional 348,715 shares in the last quarter. American Century Companies Inc. grew its position in ABIOMED by 99.8% during the third quarter. American Century Companies Inc. now owns 484,142 shares of the medical equipment provider’s stock worth $81,626,000 after buying an additional 241,868 shares in the last quarter. Finally, FMR LLC acquired a new stake in ABIOMED during the second quarter worth about $32,609,000. 90.75% of the stock is currently owned by institutional investors and hedge funds.

ABIOMED (NASDAQ ABMD) opened at $215.11 on Monday. ABIOMED has a 1-year low of $103.53 and a 1-year high of $216.15. The company has a current ratio of 5.84, a quick ratio of 5.20 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $9,511.33, a PE ratio of 105.97, a price-to-earnings-growth ratio of 2.84 and a beta of 0.15.

ABIOMED (NASDAQ:ABMD) last posted its earnings results on Thursday, October 26th. The medical equipment provider reported $0.54 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.38 by $0.16. ABIOMED had a return on equity of 13.89% and a net margin of 18.27%. The company had revenue of $132.80 million for the quarter, compared to analyst estimates of $131.18 million. During the same period last year, the company earned $0.20 earnings per share. The business’s revenue was up 28.9% compared to the same quarter last year. equities research analysts anticipate that ABIOMED will post 2.41 EPS for the current year.

WARNING: This news story was first posted by American Banking News and is owned by of American Banking News. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright legislation. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2018/01/15/abiomed-inc-abmd-given-consensus-recommendation-of-buy-by-analysts.html.

About ABIOMED

ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.

Analyst Recommendations for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.